Featured News

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

Researchers found that roughly one-third of celiac patients reported using probiotics for perceived health benefits, despite the lack of evidence that probiotics are an effective treatment for celiac disease symptoms.

There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates.

The FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.

Researchers at Boston Children’s Hospital are evaluating access to gluten-free food prior to and during the COVID-19 pandemic. We invite anyone with celiac disease following a gluten-free diet to complete this 3-5 minute survey.

Researchers at MassGeneral Hospital for Children have found substantial gut microbiome changes in the intestines of at-risk infants before celiac disease onset.

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.